Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint Therapeutics. The acquisition remains subject to stockholder approval and regulatory clearances.

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma. Sun Pharma announced ...

"Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...

Candel Therapeutics (CADL) together with IDEA Pharma announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and ...

The company share took a dive after the company informed, through an exchange filing, that Lyndra Therapeutics Inc, a company that Sun Pharma has stakes in, had ceased operations. Read Also Roshni ...

(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP) announced Monday that its interventional psychiatry network HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical following ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX ... with Endo Operations Limited (“Endo”) and Paladin Pharma Inc., to acquire the Paladin business (“Paladin”).

Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics ... sales of cosibelimab. Sun Pharma was founded in 1983 and ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun ...

India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment of $355M. The deal involves an ...